The committee observed the absence of concrete regulatory intervention on pricing and insurance coverage that continue to make CGMs and essential diabetic medicines unaffordable.
Hot this week
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Get important news delivered directly to your inbox and stay connected!
